Expression of the TGF-b1/p53 Target SERPINE1 Gene in Alzheimer’s Dementia: Molecular Mechanisms and Therapeutic Opportunities
DOI:
https://doi.org/10.12974/2309-6128.2014.02.01.1Abstract
Editorial
References
Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131- 1135. http://dx.doi.org/10.1016/0006-291X(84)91209-9
Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399(6738 suppl): A23- A31. http://dx.doi.org/10.1038/399a023
Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM. Cleavage of Alzheimer's amyloid precursor protein by ????- secretase occurs at the surface of neuronal cells. Biochemistry 1999; 38: 9728-9734. http://dx.doi.org/10.1021/bi9906827
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, et al. ????-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-741. http://dx.doi.org/10.1126/science.286.5440.735
Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and ????APP processing. Nature 2000; 407: 48-54. http://dx.doi.org/10.1038/35024009
Periz G, Fortini ME. Proteolysis in Alzheimer's disease: can plasmin tip the balance? EMBO Reports 2000; 1: 477-478. http://dx.doi.org/10.1093/embo-reports/kvd124
Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, et al. The plasmin system is induced by and degrades amyloid-???? aggregates. J Neurosci 2000; 20: 3937-3946.
Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid ????-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999; 38: 11570-11576. http://dx.doi.org/10.1021/bi990610f
Wnendt S, Wetzels I, Gunzler WA. Amyloid ???? peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb Res 1997; 85: 217-224. http://dx.doi.org/10.1016/S0049-3848(97)00006-6
Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP ????- cleavage and A???? degradation and is reduced in Alzheimer's disease brains. EMBO Reports 2000; 1: 530-535. http://dx.doi.org/10.1093/embo-reports/kvd107
Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. J Biol Chem 2001; 276: 33293-33296. http://dx.doi.org/10.1074/jbc.R100016200
Vivien D, Buisson A. Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metabol 2000; 20: 755-764. http://dx.doi.org/10.1097/00004647-200005000-00001
Hino H, Akiyama H, Iseki E, Kato M, Kondo H, et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. Neurosci Lett 2001; 297: 105-108. http://dx.doi.org/10.1016/S0304-3940(00)01679-7
Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein e receptor, the ????2-macroglobulin receptor/ low-density-lipoprotein receptor - related protein. Ann Neurol 1995; 37: 211-217. http://dx.doi.org/10.1002/ana.410370212
McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195- 218. http://dx.doi.org/10.1016/0165-0173(95)00011-9
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. Correlative memory deficits, A???? elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102. http://dx.doi.org/10.1126/science.274.5284.99
Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-???? (A????) degradation and inhibits A????-induced neurodegeneration. J Neurosci 2003; 23: 8867-8871.
Flavin MP, Zhao G, Ho LT. Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. GLIA 2000; 29: 347-354. http://dx.doi.org/10.1002/(SICI)1098- 1136(20000215)29:4<347::AID-GLIA5>3.0.CO;2-8
Higgins PJ. The TGF-????1/upstream stimulatory factorregulated PAI-1 gene: potential involvement and a therapeutic target in Alzheimer’s disease. J Biomed Biotechnol 2006: ID15792: 1-6. http://dx.doi.org/10.1155/JBB/2006/15792
Hultman K, Blomstrand F, Nilsson M, Wilhelmsson U, Malmgren K, Pekny M, Kousted T, Jern C, Tjärnlund-Wolf A. Expression of plasminogen activator inhibitor-1 and protease nexin-1 in human astrocytes: Response to injury-related factors. J Neurosci Res 2010; 88: 2441-2449.
Liu RM, van Groen T, Katre A, Cao D, Kadisha I, et al. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer’s disease. Neurobiol Aging 2011; 32: 1079-1089. http://dx.doi.org/10.1016/j.neurobiolaging.2009.06.003
Akhter H, Katre A, Li L, Liu X, Liu RM. Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease. J Alzheimers Dis 2011; 26: 767-778.
Samarakoon R, Dobberfuhl AD, Cooley C, Overstreet JM, Patel S, Goldschmeding R, Meldrum KK, Higgins PJ. Induction of renal fibrotic genes by TGF-????1 requires EGFR Activation, p53 and reactive oxygen species. Cell Signal 2013; 25: 2198-2209. http://dx.doi.org/10.1016/j.cellsig.2013.07.007
Overstreet JM, Samarakoon R, Meldrum KK, Higgins PJ. Redox control of p53 in the Transcriptional regulation of TGF- ????1 target genes through SMAD cooperativity. Cell Signal 2014; 26: 1427-1436. http://dx.doi.org/10.1016/j.cellsig.2014.02.017
Barker R, Kehoe PG, Love S. Activators and inhibitors of the plasminogen system in Alzheimer's disease. J Cell Mol Med 2012; 16: 865-876. http://dx.doi.org/10.1111/j.1582-4934.2011.01394.x
Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, et al. Enhanced clearance of A???? in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci USA 2008; 105: 8754-8759. http://dx.doi.org/10.1073/pnas.0710823105
Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodeling. Nature 2007; 447: 178-182. http://dx.doi.org/10.1038/nature05772
Sarma B, Singh N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology 2011; 215: 677-687. http://dx.doi.org/10.1007/s00213-011-2164-0
Dienel GA, Liu K, Cruz NF. Local uptake of 14C-labeled acetate and buyrate in rat brain in vivo during spreading cortical depression. J Neuroscience Res 2011; 66: 812-820. http://dx.doi.org/10.1002/jnr.10063
Kim HJ, Leeds P, Chuang D-M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 2009; 110: 1226-1240. http://dx.doi.org/10.1111/j.1471-4159.2009.06212.x
Wyss-Coray T, lin C, Sanan DA, Mucke L, Mashiah E. Chronic overproduction of transforming growth factor-????1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol 2000; 156: 139-150. http://dx.doi.org/10.1016/S0002-9440(10)64713-X
Lesné S, Docagne F, Gabriel C, Liot G, Lahiri DK, et al. Transforming growth factor-????1 potentiates amyloid-???? generation in astrocytes and in transgenic mice. J Biol Chem 2003; 278: 18408-18418. http://dx.doi.org/10.1074/jbc.M300819200
Lesné S, Blanchet S, Docagne F, Liot G, Plawinski L, et al. Transforming growth factor-????1-modulated cerebral gene expression. J Cereb Blood Flow Metabol 2002; 22: 1114- 1123. http://dx.doi.org/10.1097/00004647-200209000-00009
